In view of the current developments regarding the coronavirus and in consultation with the chairmen, we unfortunately will postpone the event to 2022.
We very much regret and are currently examining the possibility of a new date in spring time 2022. You will receive further information in due time.
In recent years, Advanced Therapy Medicinal Products (ATMP) have evolved into a promising and highly hoped-for medical approach to cure a broad spectrum of inherited and acquired human diseases, ranging from cancer to immunological disorders and rare diseases. However, the path from development to clinical application is not yet routine.
The conference will highlight the challenging field of gene and cell therapeutics.
Advances in development and manufacturing will be presented at ATMP 2021, as well as quality control methods and regulatory aspects: The focus is on the path to safe and beneficial advanced therapies for the patient.
The conference will highlight the challenging field of gene and cell therapeutic approaches, especially focusing on the following topics:
Ulf Bethke Miltenyi Biotec GmbH, Bergisch Gladbach
Cornelia Kasper University of Natural Resources and Life Sciences, Vienna
Konrad Kohler BioMedTech, Forschungscampus Reutlingen
Thomas Noll University of Bielefeld
Ralf Pörtner Technical University Hamburg
Bernd Schröder Miltenyi Biotec GmbH, Teterow
Karin Tiemann DECHEMA e.V., Frankfurt am Main
Andrea Traube OPTIMA pharma GmbH, Schwäbisch Hall
Roland Wagner Technical University Braunschweig
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
The challenges and issues of manufacturing and analytics of gene and cell therapeutics are very different from all other therapeutics, including biopharmaceuticals. A key factor of success is the management of multiple challenges addressing safety, purity and potency of these advanced therapies.
Robust and reliable manufacturing processes are still far from routine. Efficient gene transfer vectors, delivering the therapeutic gene into the target cells without causing any associated pathogenic effect, need to be developed and produced in large-scale.
Depending on the complexity and individuality of this product class, cell therapy manufacturing processes may comprise consistent procedures of culture, expansion, genetic manipulation, stimulation, and in case of treatments of multiple patients, cell banking. Analytics and quality control need to be adapted to this broad range of complex manufacturing processes ensuring adequate safety, purity and potency of the final products.
The conference is an initiative of the DECHEMA working groups Cell Culture Technology and Medical Biotechnology.